Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China

Published:2020-08-14 Issue:30 Volume:26 Page:4465-4478
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:
Short-container-title:WJG

Author:

Wang Dong-Xu,Yang Xu,Lin Jian-Zhen,Bai Yi,Long Jun-Yu,Yang Xiao-Bo,Seery Samuel,Zhao Hai-Tao

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference26 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Hepatocellular Carcinoma

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

4. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies

5. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Commentary: Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases;Frontiers in Oncology;2024-04-05

2. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study;Liver International;2024-01-30

3. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study;European Journal of Gastroenterology & Hepatology;2024-01

4. Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma;International Journal of Biological Sciences;2024

5. Deciphering essential druggable genes reveals potential immune-inflammatory axis in hepatocellular carcinoma;Computers in Biology and Medicine;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3